About 400 reports

Genetic and Rare Diseases.

  • Immunotherapy
  • AbbVie Inc.
  • Amryt Pharma plc
  • Celgene Corporation
  • Fibrocell Science, Inc.

There is ongoing research involving stem cell in the areas of diseases such as macular degeneration, neurological conditions such as Parkinson' s disease, Huntingdon' s disease and motor neuron disease, diabetes, spinal cord injury, myocardial infarction a

  • Immunotherapy
  • United States
  • World
  • AbbVie Inc.
  • Amgen Inc.

The company is offering various technologies to diagnose genetic diseases, and it has a robust portfolio.

  • Colorectal Cancer
  • Immunotherapy
  • World
  • Forecast
  • Market Size
  • THREATS

THE COMPANY' S CURRENT THERAPEUTIC AREAS OF FOCUS SPAN ACROSS GENETIC DISEASES, HEMATOLOGY, IMMUNOLOGY, OPHTHALMOLOGY, NEUROSCIENCE, AND ONCOLOGY.

  • Colorectal Cancer
  • Immunotherapy
  • AbbVie Inc.
  • Pfizer Inc.
  • Remicade group

The major factors driving the growth of the market are government and private funding to support the development of regenerative medicine, rising prevalence of chronic diseases, genetic disorders, and rapid growth of aging population.

  • Immunotherapy
  • World
  • AbbVie Inc.
  • Amgen Inc.
  • F. Hoffmann-La Roche Ltd.
  • 1.1 Colorectal Cancer

Most colorectal cancers are due to old age and lifestyle factors with only a small number of cases with underlying genetic disorders.

  • Colorectal Cancer
  • United States
  • Forecast
  • Epigenomics AG
  • Exact Sciences Corp.

Gene therapy is the transfer of genetic material (DNA or RNA) into the cells of a patient to treat a genetic disease.

  • Immunotherapy
  • United States
  • AbbVie Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company

Disease susceptibility is extremely complex due to the involvement of various genetic and environmental factors.

  • Immunotherapy
  • Musculoskeletal Disorder
  • Therapy
  • United States
  • World

Unlike NSCLC, SCLC is not associated with a specific somatic mutation and the genetic alterations leading to disease progression are still unclear.

  • Colorectal Cancer
  • Immunotherapy
  • Therapy
  • United States
  • Merck & Co., Inc.

Discovery Small molecule Thymidylate Synthase (TYMS or EC ##. ##. ##. ##) Synthetic Peptides to Inhibit Kallikrein for Immunology, Dermatological and Genetic Disorders Queensland University of Technology Discovery Synthetic peptide Kallikrein (EC ##. ##. ##. )

  • Immunotherapy
  • AbbVie Inc.
  • Allergan plc
  • Amgen Inc.
  • Apricus Biosciences, Inc.

GENETIC FACTORS ARE ALSO A CONTRIBUTOR TO IPF; AROUND ## IN ## PEOPLE WITH IPF HAVE ANOTHER FAMILY MEMBER WITH THE DISEASE DUE TO A DISEASE CALLED FAMILIAL IDIOPATHIC FIBROSIS.

  • Immunotherapy
  • Market Size
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Biologics, Inc.

" Cancer isn' t a one-size-fits all disease.

  • Colorectal Cancer
  • Immunotherapy
  • Medical Biotechnology
  • Therapy
  • United States

Unaffected individuals may carry one or more alleles associated with psoriasis, and if no other genetic or environmental factors necessary for disease presentation are present, they will not develop the disease.

  • Immunotherapy
  • Market Size
  • Allergan plc
  • Apricus Biosciences, Inc.
  • Pfizer Inc.

There are currently no drugs specifically targeting the TNBC patient segment, due to the lack of exploitable targets or a genetically heterogeneous disease phenotype.

  • Colorectal Cancer
  • Immunotherapy
  • AstraZeneca PLC
  • Novartis AG
  • Roche Group

Cancer is a genetic disease that is conventionally treated by surgery, radiation therapy, chemotherapy, hormonal therapy, and immunotherapy.

  • Colorectal Cancer
  • Immunotherapy
  • Medical Biotechnology
  • World
  • Forecast
  • Pharmaceutical Industry, Clinical Trial Size by Molecule Type, 2006-Q1 2017
  • Pharmaceutical Industry, Median Clinical Trial Size by Therapy Area (Participants),

The most substantial differences were seen in genetic disorders, in which the medium recruitment volume was ##, and infectious diseases, in which it was ##.

  • Colorectal Cancer
  • Immunotherapy
  • Pharmaceutical
  • Therapy
  • Market Size

THIS LEADS TO A CASCADE OF GENETIC MUTATIONS DUE TO SYNERGISTIC INTERPLAY OF SEVERAL EPIGENETIC MECHANISMS.

  • Colorectal Cancer
  • Immunotherapy
  • North America
  • United States
  • Novartis AG

Mar ##, 2018: CRISPR enhances gene therapy to fight inherited diseases Gene therapy has shown promise in treating inherited genetic diseases, but a major issue that has frustrated scientists remains: Replacing a " bad" gene with a healthy one often is a s

  • Colorectal Cancer
  • Immunotherapy
  • Infectious Disease
  • United States
  • Mallinckrodt plc

THE GENETIC ABNORMALITIES IN FOUR OF THESE EIGHT PATIENTS WERE FOUND TO BE ASSOCIATED WITH HIGH RISK DISEASE.

  • Colorectal Cancer
  • Immunotherapy
  • Company
  • Market Size
  • Juno Therapeutics Inc.

China Journal of Breast Disease; ##: ##-##.

  • Colorectal Cancer
  • Immunotherapy
  • Novartis AG
  • Pfizer Inc.
  • Roche Group

AMD IS A COMPLEX GENETIC DISEASE, THEREFORE GENETIC RISK SCORE ANALYSIS OF COMMON VARIANTS CAN BE OF VALUE IN DETERMINING AN INDIVIDUAL' S RISK OF DEVELOPING THE DISEASE.

  • Colorectal Cancer
  • Immunotherapy
  • Allergan plc
  • Novartis AG
  • Ophthotech Corporation

(USA) ##.

  • Immunotherapy
  • Medical Biotechnology
  • Protein Therapy
  • World
  • Market Shares

Cancer is a genetically driven disease, with accumulative mutations providing selective advantages to the cells in the context of the specific tissue site, followed by clonal expansion (Greaves and Maley, 2012).

  • Colorectal Cancer
  • Immunotherapy
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Johnson & Johnson

RISK FACTORS FOR THE DISEASE INCLUDE ENVIRONMENTAL CONDITIONS, GENETIC TRAITS, AND LIFESTYLE CHOICES.

  • Colorectal Cancer
  • Immunotherapy
  • AstraZeneca PLC
  • Novartis AG
  • Pfizer Inc.

There is a lot of interest in this, and it' s a whole new mechanism that was discovered through some rare genetic diseases.

  • Immunotherapy
  • AbbVie Inc.
  • Clearside Biomedical, Inc.
  • pSivida Corp.
  • Santen Pharmaceutical Co., Ltd.

Journal of Global Infectious Diseases; ##(##): ##- ##.

  • Colorectal Cancer
  • Immunotherapy
  • Market Size
  • Juno Therapeutics Inc.
  • Merck & Co., Inc.

(USA) ##.

  • Immunotherapy
  • Medical Biotechnology
  • Therapy
  • World
  • Market Shares

(Australia) ##.

  • Immunotherapy
  • Medical Biotechnology
  • Pharmaceutical
  • World
  • Market Shares

Cancer is a genetically driven disease, with iterative mutations providing selective advantages to the cells in the context of the specific tissue site, followed by clonal expansion (Greaves and Maley, 2012).

  • Colorectal Cancer
  • Immunotherapy
  • Celgene Corporation
  • Novartis AG
  • Pfizer Inc.
  • GLOBAL MARKETS DIRECT REPORT COVERAGE

WHO: NantOmics, LLC WHAT: Sarcoma Session WHEN: June ##, ##:##-##:## AM CST WHERE: S##a, McCormick Place Presentation Summary MAR ##, 2015: CANCER DRUG MAY REDUCE BLEEDING IN PATIENTS WITH RARE GENETIC DISORDER, HHT A cancer drug that helps keep tumors from growing blood vessels may

  • Colorectal Cancer
  • Immunotherapy
  • Pharmaceutical
  • Therapy
  • Novartis AG